Literature DB >> 34052963

A Comparison of Attitudes, Comfort, and Knowledge of Clozapine Among Two Diverse Samples of US Psychiatrists.

Robert O Cotes1, A Umair Janjua2, Beth Broussard2, David Lazris2, Ayesha Khan3, Yunshen Jiao4, Sarah L Kopelovich5, David R Goldsmith2.   

Abstract

Considerable variation in clozapine utilization exists across the United States, and little is known about the perspective of psychiatrists in states with low clozapine use. To better understand clozapine practices, attitudes, and barriers, a survey was administered to a group of southeastern state conference attendees (SSCA; N = 86). The same survey was administered to psychiatrists belonging to a national community psychiatry organization (AACP; N = 57), and differences were analyzed across the two samples. In comparison to the AACP, the SSCA group felt less comfortable, perceived clozapine as less safe and effective, had fewer patients on clozapine, and were more likely to prefer antipsychotic polypharmacy to clozapine use. Across the sample, use of a myocarditis screening protocol was rare (N = 14/76; 18%) and less than half used plasma antipsychotic levels to guide dosage (N = 60/129; 47%). Continuing professional education on clozapine are needed for psychiatrists who see individuals with psychotic disorders.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Attitudes; Clozapine; Prescriber; Schizophrenia

Mesh:

Substances:

Year:  2021        PMID: 34052963      PMCID: PMC9112232          DOI: 10.1007/s10597-021-00847-0

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  33 in total

1.  Impact of audit and feedback on antipsychotic prescribing in schizophrenia.

Authors:  Amanda Wheeler; Verity Humberstone; Elizabeth Robinson; Janie Sheridan; Peter Joyce
Journal:  J Eval Clin Pract       Date:  2009-04-02       Impact factor: 2.431

2.  A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls.

Authors:  Kathlyn J Ronaldson; Paul B Fitzgerald; Andrew J Taylor; Duncan J Topliss; John J McNeil
Journal:  Aust N Z J Psychiatry       Date:  2011-04-27       Impact factor: 5.744

3.  Antipsychotic Polypharmacy.

Authors:  Adriana Foster; Jordanne King
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

4.  An Unmet Need: A Clozapine-Induced Myocarditis Screening Protocol.

Authors:  David R Goldsmith; Robert O Cotes
Journal:  Prim Care Companion CNS Disord       Date:  2017-08-03

5.  Subjective experiences of clozapine treatment by patients with chronic schizophrenia.

Authors:  J Waserman; M Criollo
Journal:  Psychiatr Serv       Date:  2000-05       Impact factor: 3.084

6.  Effectiveness of switching from antipsychotic polypharmacy to monotherapy.

Authors:  Susan M Essock; Nina R Schooler; T Scott Stroup; Joseph P McEvoy; Ingrid Rojas; Carlos Jackson; Nancy H Covell
Journal:  Am J Psychiatry       Date:  2011-05-02       Impact factor: 18.112

7.  An evaluation of subjective experiences, effects and overall satisfaction with clozapine treatment in a UK forensic service.

Authors:  Inti Qurashi; Paul Stephenson; Simon Chu; Chris Duffy; Nusrat Husain; Imran Chaudhry
Journal:  Ther Adv Psychopharmacol       Date:  2015-06

8.  Blood Draw Barriers for Treatment with Clozapine and Development of a Point-of-Care Monitoring Device.

Authors:  Deanna L Kelly; Hadar Ben-Yoav; Gregory F Payne; Thomas E Winkler; Sheryl E Chocron; Eunkyoung Kim; Christopher Kitchen; Veronika Stock; Gopal Vyas; Raymond C Love; Heidi J Wehring; Kelli M Sullivan; Stephanie Feldman; Fang Liu; Robert P McMahon; Reza Ghodssi
Journal:  Clin Schizophr Relat Psychoses       Date:  2015-07-28

Review 9.  Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

Authors:  Oliver D Howes; Rob McCutcheon; Ofer Agid; Andrea de Bartolomeis; Nico J M van Beveren; Michael L Birnbaum; Michael A P Bloomfield; Rodrigo A Bressan; Robert W Buchanan; William T Carpenter; David J Castle; Leslie Citrome; Zafiris J Daskalakis; Michael Davidson; Richard J Drake; Serdar Dursun; Bjørn H Ebdrup; Helio Elkis; Peter Falkai; W Wolfgang Fleischacker; Ary Gadelha; Fiona Gaughran; Birte Y Glenthøj; Ariel Graff-Guerrero; Jaime E C Hallak; William G Honer; James Kennedy; Bruce J Kinon; Stephen M Lawrie; Jimmy Lee; F Markus Leweke; James H MacCabe; Carolyn B McNabb; Herbert Meltzer; Hans-Jürgen Möller; Shinchiro Nakajima; Christos Pantelis; Tiago Reis Marques; Gary Remington; Susan L Rossell; Bruce R Russell; Cynthia O Siu; Takefumi Suzuki; Iris E Sommer; David Taylor; Neil Thomas; Alp Üçok; Daniel Umbricht; James T R Walters; John Kane; Christoph U Correll
Journal:  Am J Psychiatry       Date:  2016-12-06       Impact factor: 18.112

10.  Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

Authors:  Joseph P McEvoy; Jeffrey A Lieberman; T Scott Stroup; Sonia M Davis; Herbert Y Meltzer; Robert A Rosenheck; Marvin S Swartz; Diana O Perkins; Richard S E Keefe; Clarence E Davis; Joanne Severe; John K Hsiao
Journal:  Am J Psychiatry       Date:  2006-04       Impact factor: 19.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.